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Background: Taxanes such as paclitaxel and docetaxel are used successfully to treat breast cancer, usually in
combination with other agents. They interfere with microtubules causing cell cycle arrest; however, the
mechanisms underlying the clinical effects of taxanes are yet to be fully elucidated.
Methods: Isogenic paclitaxel resistant (PACR) MDA‐MB‐231, paclitaxel resistant ZR75‐1 and docetaxel resistant
(DOCR) ZR75‐1 cell lines were generated by incrementally increasing taxane dose in native cell lines in vitro. We
used aCGH analysis to identify mechanisms driving taxane resistance.
Results: Taxane resistant cell lines exhibited an 18-170 fold increased resistance to taxanes, with the ZR75-1 resistant
cell lines also demonstrating cross resistance to anthracyclines. Paclitaxel treatment of native cells resulted in a G2/M
block and a decrease in the G1 phase of the cell cycle. However, in the resistant cell lines, minimal changes were
present. Functional network analysis revealed that the mitotic prometaphase was lost in the resistant cell lines.
Conclusion: This study established a model system for examining taxane resistance and demonstrated that both MDR
and mitosis represent common mechanism of taxane resistance.
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Breast tumours exhibit a wide degree of heterogeneity
and diversity at both the cellular and molecular level.
The taxanes, paclitaxel and docetaxel, are used success-
fully to treat breast cancer, alone or in combination with
other agents [1]. Taxanes act by interfering with the
spindle microtubule dynamics of the cell causing cell cycle
arrest followed by cell death [2]. A significant proportion
of patients progress despite treatment with taxane
containing chemotherapy and there is a pressing need for
both novel therapeutic options for patients failing taxane
therapy and predictive biomarkers to select patients likely
to benefit. Overexpression of P-glycoprotein (PgP/MDR1)* Correspondence: John.Bartlett@oicr.on.ca
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unless otherwise stated.is one of the most recognised mechanisms causing taxane
resistance [3,4]. However, several other candidate
predictive biomarkers have been proposed in recent
studies (AKT/HER2/TLE3) [5-7], but to date no robust,
predictive diagnostic assay for taxane benefit or resist-
ance has emerged. Whilst data suggests some patients
are intrinsically resistant to taxanes and others acquire
resistance to taxanes as treatment advances there is
insufficient understanding of the clinical mechanisms
underlying taxane resistance to develop either rational
novel therapeutic or diagnostic approaches to target
taxane based chemotherapy.
Progress in “targeting” conventional therapeutics such
as anthracyclines and taxanes has been slow and has
been hampered, in part, by a lack of focus and under-
standing of the key molecular events that lead to drug
response or resistance in the clinical setting. Without
significant progress in identifying the key molecular
pathways driving drug resistance in vivo, we run the riskLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lecular diagnostics in a stochastic and largely unfocused
manner.
Genome wide profiling of breast tumours is a powerful
tool that can be used to correlate tumour characteristics
to clinical outcome in patients. Many extensive studies
have proposed novel and molecular subtypes of breast
cancer which may have clinical relevance [8-12]. How-
ever few, if any, have proven effective as a basis for
either targeting existing treatments or identifying novel
therapeutic approaches in the context of drug resistance.
The overall aim of this study was to generate isogenic
taxane-resistant breast cancer cell lines and elucidate the
mechanisms that are driving resistance to taxanes in a
pre-clinical model system. The studies summarised here
characterise taxane resistant cell lines derived by the in-
cremental increase of paclitaxel or docetaxel dose. The
results presented demonstrate the ZR75-1 resistant cell
line harbour cross-resistance to anthracyclines. An aCGH
profile demonstrated a loss of mitotic pathways in the re-
sistant cell lines indicating a potential theranostic pathway.
Methods
Cell culture and reagents
The breast cancer cell lines MDA-MB-231 and ZR75-1
(ATCC, Cedarlane Laboratories Ltd, Burlington, Canada)
were cultured as monolayer in DMEM supplemented
with 10% foetal calf serum, 10 mM glutamine and peni-
cillin and streptomycin. Paclitaxel (Sigma, Oakville,
Canada), docetaxel (Sigma, Oakville, Canada), epirubicin
(Sigma, Oakville, Canada), doxorubicin (Sigma, Oakville,
Canada) and carboplatin (Sigma, Oakville, Canada) were
dissolved in dimethyl sulphoxide (DMSO) (Sigma,
Oakville, Canada). Concentrated stock solutions were
stored at -20°C. Drug resistant isogenic daughter cell
lines were derived by incremental increases in drug con-
centrations over time until a stable taxane resistant
phenotype was acquired. Cells were in each concentra-
tion of drug for two passages and until confluent, this
ranged between 1-4weeks dependent on the dose. The
following isogenic sub-lines were selected for further
characterisation alongside each parent line: MDA-MB-
231 25nM and 50nM paclitaxel resistant (MDA-MB-
231 25PACR and MDA-MB-231 50PACR), ZR75-1
25nM and 50nM paclitaxel resistant (ZR75-1 25PACR,
ZR75-1 50PACR) and 25nM and 50nM docetaxel resist-
ant (ZR75-1 25DOCR, ZR75-1 50DOCR).
IC50 and proliferation rates of parental and isogenic drug
resistant lines
Dose response curves were set up by treating cells with
increasing doses of the appropriate taxane: 0, 0.3, 1, 3,
10, 30, 100, 300, 1000 or 3000nM of either paclitaxel or
docetaxel. Cross resistance to epirubicin, doxorubicinand carboplatin was assessed in a similar manner. Cell
suspensions (100μl) were seeded in triplicate at a density
of 30,000 cells/ml in 96 well plates and grown for 24
hours, washed and treated with drug for 72 hours. After
72 hours 100μl of growth media containing 10μl of
CCK8 (Promega, Madison, USA) was added to each well
for 3 hours at 37°C. The plates were then shaken for 10
minutes and optical density (OD) recorded at 450nm.
IC50s were calculated using GraphPad Prism 5 (San
Diego, USA). Stability of taxane resistance in MDA-
MB-231 25PACR was assessed by maintaining the cells
for 6 months with or without paclitaxel added to the
growth medium. MDA-MB-231 parental cells were
maintained without paclitaxel for an equivalent period
for comparison.
Flow cytometry
For cell cycle and DNA content analyses, native and re-
sistant cells were plated in equal numbers into 6-well
plates and synchronized by serum starvation overnight.
Cells were then incubated with the appropriate con-
centration of taxane (25nM or 50nM of either docetaxel
or paclitaxel), DMSO control or media alone control.
The cells were collected after 24 and 48 hours, fixed
with 80% ethanol and incubated with 2mg/ml RNase A
(Sigma, Oakville, Canada) and 0.1mg/ml propidium iod-
ide (Sigma, Oakville, Canada) for 30 minutes prior to
analysis by flow cytometry. Data was collected by FACS
Canto II and FACS Diva (both from BD Biosciences,
Mississauga, Canada), and analyzed by FlowJo (Treesta,
San Carlos, USA).
DNA extraction and sample preparation for array
Comparative Genomic Hybridisation
DNA was extracted from cells using the Qiagen Blood
and Cell Culture Maxi kit (Qiagen, Toronto, Canada).
DNA was stored in TE buffer pH 8.0 at 4°C.
Microarray CGH
Cell line DNA was analysed on the Breakthrough Breast
Cancer human CGH 4.6K 1.12 arrays as previously de-
scribed [13]. Briefly, 1 μg of test and normal female
genomic DNA, from pooled donor samples, was directly
labelled with Cy3-dCTP or Cy5-dCTP (Amersham
BioSciences, Amersham, UK) using a Bioprime labelling
kit (Invitrogen, Paisley, UK) according to the manufac-
turer's protocol modified to incorporate 1.0 mM Cy dye,
0.6 mM dCTP, and 1.2 mM dATP, dGTP and dTTP. Un-
incorporated nucleotides were removed with MinElute
purification columns (Qiagen, Crawley, UK). The la-
belled DNA was co-precipitated with 100 μg of Cot1
(Invitrogen, Paisley, UK), resuspended in hybridization
buffer [50% formamide, 10% dextran sulphate, 2× SSC,
2% SDS, 2 mg of yeast tRNA (Invitrogen, Paisley, UK)],
Table 1 IC50 values (nM) for paclitaxel, docetaxel, epirubicin, doxorubicin and carboplatin in isogenic MDA-MB-231 and
ZR75-1 cell lines
Paclitaxel Docetaxel Epirubicin Doxorubicin Carboplatin
MDA-MB-231 1.6 0.8 35.15 35.64 208
MDA-MB-231 25PACR 29.61 6.4 34.25 61.38 212
MDA-MB-231 50PACR 89.98 10.16 30.39 30.12 266
ZR75-1 2.76 3.1 16.96 24.18 342.6
ZR75-1 25PACR 470.8 134.3 330.7 324.2 342.8
ZR75-1 50PACR 489.1 489.1 318.7 224.4 369.2
ZR75-1 25DOCR 41.24 42.13 3516 255.5 408.8
ZR75-1 50DOCR 310.1 47.24 506.9 676.7 386.9
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min at 37°C. Slides were blocked in 10% BSA–50% form-
amide solution at 42°C for 45 min. The probe was sub-
sequently applied to the slide and hybridized overnight
at 42°C. Slides were washed in 2× SSC, 0.1% SDS for 15
min at 45°C; 2× SSC, 50% formamide for 15 min at 45°C;
2× SSC, 0.1% SDS for a subsequent 30 min at 45°C; and fi-
nally two 15-min washes of 0.2× SSC at room temperature.
Slides were centrifuged at 1200 rpm for 2 min to dry. Each
experiment was performed in duplicate as a dye swap to
eliminate any labelling bias.Image acquisition and data analysis
Slides were scanned using an Axon 4000B scanner (Axon
Instruments, Burlingame, CA, USA) and images were
analysed using Genepix Pro 4.1 software (Axon Instru-
ments). The median localized background slide signal
for each clone was subtracted and each clone Cy5/Cy3
ratio subjected to print-tip loess normalization [14].
Dye swap experiments were collated, bacterial artificial
chromosome (BAC) clone replicate spots averaged, and
clones with poor reproducibility between replicates
excluded (standard deviation >0.2).Figure 1 MDA-MB-231 25PACR cells maintained resistance to
paclitaxel after prolonged culture without exposure to taxane.
MDA-MB-231 25PACR cells were separated into two groups: one
maintained and passaged, as normal in the presence of paclitaxel
(white bar), the other was maintained and passaged in the absence
of drug (grey bar)for a period of six months. The native cells are
represented by the black bar. Cells were incubated with varying
concentrations of paclitaxel and cell viability determined by CCK-8
assay. The X axis shows the increasing paclitaxel concentration
measured in nM. The Y axis represents the percentage of cells with
untreated cells being used as a baseline of 100%.Network-based analysis
To examine whether genes showing common copy num-
ber gains or copy number losses across all three cell
lines belong to a specific pathway, we conducted func-
tional analysis of the common genes using Cytoscape
Reactome Functional Interaction (FI) plugin in Cytos-
cape 3.0.2 (2013 FI network version). Genes were loaded
using the gene set format with FI annotations and linker
genes. Spectral clustering was performed to identify dis-
tinct network modules and subsequent pathway enrich-
ment was calculated. Symbols were loaded as a gene set
and interactions from the FI network 2012 version,
including FI annotations and linker genes. Network
modules were identified using spectral clustering and
Pathway Enrichment computed for each module usingthe Reactome FI plugin functions. Reactome pathways
exhibiting FDR values < 0.01 were considered enriched.MDR Resistance: RNAi Transfection of ZR75-1 resistant cells
A total of 2.6 × 105 ZR75-1 25PACR cells were trans-
fected with Lipofectamine RNAiMAX (Invitrogen, Paisley,
UK) and siRNAs (each 30nM, Dharmacon, Waltman,
USA) targeting MDR1, according to manufacturer’s
instructions. As controls, transfection reagents without
siRNAs were added (mock transfection) and cells were
transfected with siRNA targeting GAPDH. After 48h
cells were lysed for RNA analysis and 72h cells were
lysed for protein analysis. The differences in IC50 were
analysed and calculated as described above.
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Total protein lysates (20 μg) were separated by SDS-
PAGE according to standard protocols [15] and im-
munoblotting was carried out using antibodies directed
against PgP-specific MDR1 (G-1) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) diluted 1:1000, GAPDH
(14C10) (Cell Signalling, Whitby, Canada) diluted 1:5000
and β-actin (Calbiochem, La Jolla, USA) diluted 1:10000.
Horseradish peroxidase–conjugated secondary antibodies




Figure 2 Cell cycle analysis of native and resistant MDA-MB-231 and
respective resistant cell lines were treated with 25nM or 50nM of paclitaxel
distribution of cell in each phase. The histograms demonstrate the cell cyc
MDA-MB231 25PACR cells with or without 25nM paclitaxel. B MDA-MB-231
C ZR75-1 native and ZR75-1 25PACR cells with or without 25nM paclitaxel.
paclitaxel. E ZR75-1 native and ZR75-1 25DOCR cells with or without 25nM
50nM docetaxel. Standard deviation of three experiments are shown in braResults
Taxane resistant cell lines IC50s and cross resistance
The taxane resistant cell lines exhibited 18-170 fold
increased resistance to taxanes, when IC50s were compared
to those from parental cell lines, with cross resistance to
both forms of taxane observed in all cell lines (Table 1).
All ZR75-1 PACR and DOCR cell lines exhibited cross re-
sistance to anthracyclines (epirubicin and doxorubicin);
however, no cross-resistance was observed with carbo-
platin. MDA-MB-231 PACR cells were not cross-resistant
to either anthracyclines or carboplatin (Table 1).B
D
F
ZR75-1 by flow cytometry after synchronisation. The native and
. The DNA content was measured by flow cytometry to determine the
le distribution within the cell population. A MDA-MB-231 native and
native and MDA-MB231 25PACR cells with or without 50nM paclitaxel.
D ZR75-1 native and ZR75-1 25PACR cells with or without 50nM
docetaxel. F ZR75-1 native and ZR75-1 50DOCR cells with or without
ckets.
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231 25PACR cells in the absence of drug, cells were re-
challenged with taxanes and the responses compared to
parental and resistant cells cultured in the presence of
taxanes (Figure 1). A two way Anova analysis of the pro-
liferation data between the native and resistant cells with
or without paclitaxel was performed in a pairwise fash-
ion. When the two resistant cell lines were compared
there was no significant difference between the two lines
(p = 0.09728), indicating that they exhibited a very simi-
lar paclitaxel resistant phenotype.Figure 3 aCGH of taxane resistant cell lines. The plots show Log2Ratios
experiment using DNA from native cells as a reference samples and DNA f
which remain unchanged, the green dots represent the BAC clones in whi
the BAC clones in which there is an area of loss of the genome. The Log2r
chromosome order from 1 to the sex chromosomes. The p or short arm on
represent the position of the centromere. The cbs algorithm recursively spl
estimated by each permutation (re Mathworks.com). A. MDA-MB-231 Nativ
50PACR. C. ZR75-1 native cells vs ZR75-1 25PACR. D. ZR75-1 native cells vs
native cells vs ZR75-1 50DOCR.Cell cycle specific effects of taxanes
Paclitaxel treatment of native MDA-MB-231 and ZR75-
1 cells resulted in a G2/M block, and a failure to return
to the G0/G1 phase (Figure 2). The G2/M population of
the MDA-MB-231 native cells increased significantly
from 24% to 44% upon paclitaxel exposure compared
with a minimal change of 24% to 19% in the MDA-MB-
231 25PACR cells. The increase of cell population at the
G2/M phase was accompanied by a decrease of cell
population in the G1 phase of the cell cycle for the na-
tive cells; however the resistance cell lines exhibited noof test to reference signal intensity from BAC clines in an aCGH
rom resistant cells as a test sample. Navy dots represent BAC clones
ch there is an area of gain on the genome, and the red dots represent
atio is measured on the Y axis and on the X axis the genome runs in
each chromosome is followed by the q or long arm. The dotted lines
it chromosomes into segments based on the maximum t statistic
es vs MDA-MB-231 25PACR. B. MDA-MB-231 Natives vs MDA-MB-231
ZR75-1 50PACR. E. ZR75-1 native cells vs ZR75-1 25DOCR. F. ZR75-1
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taxel treatment of native ZR75-1 cells resulted in a sig-
nificant increase in the G2/M population from 18% to
72% and a decrease in the G1 population from 48% to
11%. While in the ZR75-1 25PACR cells there were min-
imal changes in the G2/M population from 20% to 30%,
there was a decrease in the G1 population of cells from
59% to 28%. Treatment of the ZR75-1 50PACR cells with
paclitaxel caused a slight decrease in the G2/M population
of cells from 14% to 8% and a slight change in the G1
population of cells from 61% to 71% (Figure 2).
Array comparative genomic Hybridisation
MDA-MB-231
The PACR cell lines were analysed and compared to the
parental controls (Figure 3A and B). Both the 25PACR
and 50PACR cells demonstrated marked gains and losses
(Table 2 and Figure 3A and B). There are three common
areas of genomic loss in the MDA-MB-231 cell lines that
extend with increasing paclitaxel resistance in chromosome
1p, 6p and 17p. Common areas of gain include 8q and 15p.
ZR75-1
In the ZR75-1 cell lines there were fewer genomic changes
that occurred once cell becomes resistant in contrast toTable 2 Common areas of loss, gain, deletion and
amplification identified by aCGH in MDA-MB-231 PACR,
ZR75-1 PACR and ZR75-1 DOCR at the two resistance levels






231 PACR 1p36.13-q44 2p25.3-23.3 6p21.1 6p21.1
6p25.3-q12 3p24.3-q13.3 2q13 1q32.3
8p 4p16.1-q12 15q11,2 4q21.21-21.22
10p 5q14.3-q31.1 16 q11.2 8p12, 8p11.21
19q 8q21.13-24.3 11q13.2











ZR75 DOCR 7q None None None
12p
16qthe MDA-MB-231 (Table 2, Figure 3C-F). There were
common areas of gains and losses in the 25PACR and
50PACR cells; losses were observed in 3p, 7q, 10p, 12p and
15p. Interestingly within region 7p22.3-q11.21 the gene
ABCB5, a member of the p-glycoprotein family, is present
and appears to be gained. There were no common areas of
gain in the ZR75-1 PACR cell lines.
25DOCR and 50DOCR cells compared with native cells
show area of loss in 7q, 12p and 16q again there were no
common areas of gain with the DOCR cell lines.
When comparing the data obtained from the PACR
and DOCR ZR75-1 cells the sole areas of common gen-
omic alterations were losses at 7q and 12p.
Combined analysis
When all areas of gain or loss across the 25nM resistant
cell lines were combined, 295 known genes were identi-
fied as lost and 306 genes gained (Figure 4A and 4B).
Following network analysis, eight modules were identi-
fied that contained significantly enriched pathways with
a False Discovery Rate (FDR) <0.01. Each module con-
tained clusters of connected genes. Module II contained
6 genes involved in the mitotic prometaphase. Interest-
ingly, all six genes were deleted in taxane resistance
cells and directly interconnected without linker genes
(Figure 4C). These findings would suggest that loss of mi-
totic prometaphase regulatory genes is a common event
associated with taxane resistance in breast cancer cells.
qRT-PCR validation of aCGH
qRT-PCR analysis was performed on the six deleted
genes present in the resistant cell lines compared to par-
ental controls. As shown in Figure 4C in the MDA-MB-
231 resistant cell lines all six of the genes were downreg-
ulated compared to the parental control cells. Within
the ZR75 cell lines downregulation of all resistant cell
lines was demonstrated with AHCTH1 and NUP133.
MLP1IP showed a decrease in expression in the both
DOCR and 50PACR cells compared to the natives while
the 25PACR cells showed an increase in expression.
MDR1 is a driver of taxane resistance in ZR75-1 cells only
No MDR‐1 protein expression was identified by western
blotting in the MDA‐MB‐231 native, MDA-MB-231
25PACR or MDA-MB-231 50PACR cell lines (Figure 5A).
There was a large increase in MDR1 protein expression in
all four taxane resistant ZR75‐1 cell lines while no expres-
sion of the protein was observed in the ZR75‐1 native line.
Western blot and cell proliferation assays were performed
after down-regulation of MDR1 using siRNA. Western
blot analysis demonstrated a reduction in MDR1 expres-
sion following transfection with siRNA (Figure 5B). In the
proliferation assay MDR1 knock-down exhibited a 14- and
34-fold reduction in the IC50 concentration of paclitaxel in
Figure 4 Network-based analysis of MDA-MB-231 25PACR, ZR75-1 25PACR and ZR75-1 25DOCR taxane resistant cell lines. A. Venn diagram
of genes within significant areas of gain. B. Venn diagram of genes within significant areas of loss in 3 cell lines. C. Mitotic prometaphase module
identified from functional interaction network analysis. D. Bar graph shows relative expression levels of AHCTH1, CENPF, PPP2R5A, NUP133, MLP1P and
NSL1 in the MDA-MB-231 native, 25PACR, 50 PACR ZR75-1 25PACR, 50PACR and ZR75-1 25DOCR and 50DOCR taxane resistant cell lines. Error bars show
standard deviation of three experiments. Asterisks indicate statistical difference * = p < 0.05, ** = p < 0.001.
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spectively (Figure 5C and D). This corroborates previous
western blot analysis suggesting MDR1 is the driver of
taxane resistance in the ZR75-1 cell lines. There were no
differences in α/β tubulin expression in either the ZR75 or
MDA-MB-231 resistant cell lines compared to the native
parental lines (Additional file 1: Figure S1). Taken together
this would suggest taxane resistance in these cell lines is at
least partially driven by MDR1 expression
Discussion
The taxanes are a useful and effective group of chemo-
therapeutic agents that can be used as front line therapy to
treat many types of cancer including breast, ovarian and
prostate. Unfortunately, taxane resistance is a considerable
clinical problem, and overcoming this is a key step toimproving breast cancer patient survival. One way of
combating this is to identify potential molecular drivers of
taxane resistance so that they can be targeted with
combination therapies to down-regulate the resistant
phenotype.
In this study, a panel of isogenic paclitaxel resistant
cell lines were generated by exposing parental cells to
increasing concentrations of the appropriate taxane
in vitro. We successfully generated daughter cell lines
with markedly increased IC50s for taxanes; demonstrating
clear resistance to these agents. Our cell cycle analysis
demonstrated, in the native/parental cells, treatment with
either docetaxel or paclitaxel resulted in a G2/M block.
However, the drug resistant cell lines were able to over-
come this G2/M block and progress through the cell cycle.
Interestingly, we demonstrated that both the MDA‐MB‐
Figure 5 Effects of MDR-1 knockdown in ZR75-1 paclitaxel resistant cells A Western blot analysis of proteins extracted from the cell
lines and probed with MDR1.Actin was used as a loading control. B. Western blot analysis of proteins extracted from ZR75-1 25PACR cells
after transfections with MDR1 siRNA. Control cells were untreated, or with transfections reagents only or with siRNA targeting GAPDH; actin was
used as a loading control. C. Graph shows the average IC50 of ZR75-1 25PACR cells after transfections with MDR1 siRNA. D. Graph shows the
average IC50 of ZR75-1 50PACR cells after transfections with MDR1 siRNA. Asterisks indicate statistical difference * = p < 0.05, ** = p < 0.001.
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docetaxel than paclitaxel which concurs with previous
studies using other cell lines [16]. Other studies have
suggested that docetaxel and paclitaxel affect different
stages of the cell cycle with paclitaxel only targeting
G2/M whilst docetaxel targets both S phase and G2/M
[17]. In our hands treatment with both docetaxel and
paclitaxel resulted in a G2/M block. Once reason that
we may not see an S phase block is due to the concen-
tration of drug that we were using. One study by
Hernández‐Vargas used synchronized cells and then
subjected them to low (2‐4nM) or high (100nM) con-
centrations of docetaxel. The low dose treatment
caused a transient arrest and the high dose cause a
prolonged arrest in mitosis. The short arrest leads to an
aberrant mitosis and aneuploidy whereas the long arrest
leads to mitotic slippage and tetraploidy [18]. A dual
mechanism of cell cycle response has also been seenwith paclitaxel treatment [19]. Low doses of paclitaxel
have been shown to inhibit or retard the progression of
mitosis and as a consequence alter microtubule dynam-
ics rather than actually increasing polymer mass
[20,21]. At higher concentrations of paclitaxel cells be-
come blocked in G2/M phase so that they cannot pro-
gress through mitosis.
Both ZR75-1 resistant cell lines showed cross-resistance
to anthracyclines. This is consistent with a clinical trial of
first-line treatment with anthracyclines followed by a
crossover to taxanes which showed reduced response to
taxanes [17], suggesting that anthracycline treatment may
induce taxane cross-resistance. At a protein level both
resistant ZR75-1 cell lines exhibited up-regulation of
MDR1 suggesting that the resistance observed in these
cells is mediated by the MDR family. The MDR family of
p-glycoproteins are a common resistance mechanism ob-
served in numerous in vitro studies. These proteins bind
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tively export them across the cellular membrane [22,23].
However, the clinical relevance of MDR genes remains to
be elucidated. No cross-resistance was detected in the
MDA-MB-231 PACR cells, consistent with previous
studies performed in MCF-7 paclitaxel resistant cell lines
[24] and suggests that a mechanism other than PgP glyco-
protein is driving this resistance.
We performed a genomic analysis of our cell lines using
aCGH. We compared each of the cell lines to DNA from
pooled female blood and then compared each of the resist-
ant lines with their respective native lines. Within the
MDA-MB-231 cell, areas on chromosome 1p, 6p and 17p
were lost and gains in chromosome 8q and 15p were ob-
served. When comparing the native MDA-MB-231 cell
line with the 50PACR cell lines, amplification at chromo-
some 1q was observed. Chromosome 1 aberrations are the
most frequently described in a variety of cancers [25]. In
breast cancer 1q gain is commonly observed across all sub-
types, however the functional driver in this region has yet
to be elucidated. There are many candidate genes; CENF,
KIF14, DTL, NEK2, CKS1B, ASPM and EXO1 each of
which are significantly associated with poor clinical out-
come in breast cancer patients [26]. Interestingly, when
functional network analysis was performed incorporating
all three paclitaxel resistant cell lines, a signalling module
which included genes controlling the mitotic prometa-
phase was identified. Five of the genes, PP2R5A, NUP133,
AHCTF1, CENPF and NSL1, within this module are
located on chromosome 1. Previously studies have demon-
strated CENPF as both a prognostic and predictive gene in
breast cancer [27]. One study showed CENPF to be asso-
ciated with poor prognosis [28]. Paclitaxel enhances the
stability of microtubules and mitosis is blocked at the
metaphase-anaphase transition with prolonged blocking
resulting in cell death. However, taxane resistant cells drug
appear to have lost the ability to control this process. Drug
resistant cells, when treated with taxane, progress through
the cell cycle without arresting in G2/M suggesting they
are bypassing a critical cell cycle checkpoint. Dysregulation
of the mitotic metaphase check point is linked to chromo-
some instability (CIN). CIN cells become aneuploid and
are associated with aggressive tumours and poor progno-
sis. CIN has been previously linked to taxane resistance in
ovarian and colorectal cancer [29,30]. Therefore, it would
suggest that once these in vitro cell lines become taxane
resistant they also become genomically unstable and there-
fore may be at greater risk of progression.
Conclusions
In conclusion, our study has established a new model
system to examine mechanisms of taxane resistance in
breast cancer with genomic analysis showing a mitotic
prometaphase as a predictor of resistance.Additional file
Additional file 1: Figure S1. Western blot analysis of proteins extracted
from the cell lines and probed with α/β Tubulin. GAPDH was used as a
loading control.
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